RxDoctor Payments Data

Ashley van Loenen

Primary Care · Decatur, ILNPI 1346580941

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 25.2% of the total. Reporting peaked in 2023 at $479 and has fallen 85.7% since, to $69 in 2025.

$1,149in general payments, 2019–2025

Across 62 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Johnson & Johnson$186
  • Neurocrine Biosciences, Inc.$145
  • Teva Pharmaceuticals USA, Inc.$132
  • Alkermes, Inc.$124
  • Otsuka America Pharmaceutical, Inc.$70
  • plus $203 from 9 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,149 in reported general payments places this provider in the 75th percentile of 150 primary care providers in Illinois.

See all primary care providers in Illinois

Medicare billing

Part B allowed, 2024
$6,358
Medicare patients
45
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide135$138,067
JardianceEmpagliflozin180$105,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$41,981
OzempicSemaglutide36$37,638
EliquisApixaban44$25,616
Incruse ElliptaUmeclidinium Bromide48$18,986
LinzessLinaclotide31$17,652
Breo ElliptaFluticasone/Vilanterol31$12,985
Bydureon BciseExenatide Microspheres15$12,760
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$12,184
XareltoRivaroxaban20$10,989
JanuviaSitagliptin Phosphate15$8,348
MyrbetriqMirabegron13$5,779
Gabapentin232$4,052
Atorvastatin Calcium581$4,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$290$17,65231 claims
Johnson & JohnsonXarelto$186$10,98920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 primary care providers in Illinois.

Other primary care in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →